Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03848416 · ClinicalTrials.gov registry record · Phase 1

A Study of Ixekizumab in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
99
Enrollment target
1
Study location

NCT03848416: Completed Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

NCT03848416 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 99 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03848416, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
99 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare three different formulations of ixekizumab. One formulation (Reference) has been approved by the Food and Drug Administration (FDA) and two formulations (Test 1 and Test 2) have not been approved. This study will compare how much of each of the three formulations get into the blood stream. Information about any side effects that may occur will also be collected.

Primary Outcome

Pharmacokinetics (PK): Maximum Concentration (Cmax) of a single dose of Ixekizumab

Conditions Studied

Healthy

Interventions

  • BIOLOGICAL Ixekizumab

Study Locations (1)

Florida

  • Covance Clinical Research Inc - Daytona Beach

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2019-01-29
Est. Completion 2019-06-07
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT03848416 record still lists

NCT03848416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Ixekizumab is the first listed.

NCT03848416 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT03848416 about?

NCT03848416 is a clinical study titled "A Study of Ixekizumab in Healthy Participants". The purpose of this study is to compare three different formulations of ixekizumab. One formulation (Reference) has been approved by the Food and Drug Administration (FDA) and two formulations (Test 1 and Test 2) have not been approved. This study will compare how much of each of the three formulati...

What is the current status of trial NCT03848416?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2019-01-29. Estimated completion is 2019-06-07.

What conditions does trial NCT03848416 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT03848416?

The interventions under investigation include: Ixekizumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT03848416?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03848416 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03848416's enrollment target sits among peer trials

99 241st of 1090 higher than 849 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03965234 · 99 participants · Phase 1

    Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

  • NCT04022616 · 99 participants

    Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

  • NCT04042844 · 99 participants · Phase 2

    A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

  • NCT04143724 · 99 participants · Phase 2

    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03848416, the US trial registry maintained by the National Library of Medicine. NCT03848416 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.